Craig-Hallum upgraded CareDx to a Buy rating and raised its price target to $64 following a set of near-term and long-term growth drivers. The analyst cited expanded coverage and approved indications, plus faster growth momentum tied to CareDx’s acquisition of Naveris, which accelerated the company’s oncology and liquid biopsy franchise. The note emphasized reimbursement economics and potential future label use for CareDx’s AlloSure Kidney assay beyond organ rejection detection, including subclinical injury, prognosis and therapy decision-making. It also highlighted HeartCare uptake dynamics linked to evidence for biopsy yield and independent prognostic value. Finally, Craig-Hallum pointed to NavDx growth and the prospect that additional assays—such as AlloHeme—could contribute to revenue later, even if the bank expects limited impact until 2028.